FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118404775> ?p ?o ?g. }

• W3118404775 endingPage "e001719" @default.
• W3118404775 startingPage "e001719" @default.
• W3118404775 abstract "Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.We conducted a retrospective cohort study of patients with melanoma receiving ICI from July 2015 through December 2017 at the Cleveland Clinic. TE, including VTE events of deep venous thrombosis, pulmonary embolism, visceral vein thrombosis, and ATE events of myocardial infarction, stroke, peripheral arterial embolism, or transient ischemic attack after ICI initiation were identified. Overall survival (OS) from ICI initiation was estimated by Kaplan-Meier and Cox hazard models; associations between TE, ICI regimen, and clinical risk factors were evaluated using log-rank test.The study population comprised 228 patients with median age of 65 years (23-91 years), 67% male, and median follow-up of 27.3 months. Pembrolizumab was most commonly used (38.7%), followed by combination of ipilimumab plus nivolumab (29.4%), ipilimumab (20%), and nivolumab (12.3%). Most had stage IV disease (81.1%) and 11% had brain metastases (BM) at treatment initiation. Fifty-one TE events occurred in 47 patients (20.6%), including 37 (16.2%) VTE and 14 (6.1%) ATE. Cumulative incidence of TE after ICI initiation was 9.3% (95% CI: 6.0% to 13.6%) at 6 months, and 16.0% (95% CI: 11.6% to 21.2%) at 12 months. The 6-month and 12-month VTE cumulative incidence rates were higher with combination ICI than single agent (16.7% vs 5.0% and 21.3% vs 9.5%, respectively; p=0.02). Risk factors significantly associated with VTE in multivariate analysis included combination ICI (HR 2.70; 95% CI: 1.28 to 5.70; p=0.009), Khorana Score ≥1 (HR 2.24; 95% CI: 1.06 to 4.74; p=0.03), history of coronary artery disease (HR 2.71; 95% CI: 1.16 to 6.29); p=0.02), and anticoagulation at treatment start (HR 4.14; 95% CI: 1.60 to 10.7; p=0.003). Of patients without BM, OS was worse in patients with TE compared with those without (2-year OS 50.8% vs 71.3%; HR 2.27; 95% CI: 1.36 to 3.79; p=0.002), when adjusted for age and stage.ICI is associated with a high incidence of TE in patients with melanoma, with higher rates with combination therapy; TE is associated with substantial worsening of survival. Further studies are needed to identify pathophysiology, biomarkers, and preventive approaches." @default.
• W3118404775 created "2021-01-18" @default.
• W3118404775 creator A5002744671 @default.
• W3118404775 creator A5017302019 @default.
• W3118404775 creator A5035031332 @default.
• W3118404775 creator A5039576853 @default.
• W3118404775 creator A5057402683 @default.
• W3118404775 creator A5064410348 @default.
• W3118404775 date "2021-01-01" @default.
• W3118404775 modified "2023-10-15" @default.
• W3118404775 title "Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival" @default.
• W3118404775 cites W1938806758 @default.
• W3118404775 cites W1964235315 @default.
• W3118404775 cites W1969719203 @default.
• W3118404775 cites W1971949029 @default.
• W3118404775 cites W1978080273 @default.
• W3118404775 cites W1994861753 @default.
• W3118404775 cites W1995391277 @default.
• W3118404775 cites W1996600303 @default.
• W3118404775 cites W2005281127 @default.
• W3118404775 cites W2007086823 @default.
• W3118404775 cites W2014643166 @default.
• W3118404775 cites W2033150840 @default.
• W3118404775 cites W2064982023 @default.
• W3118404775 cites W2066763853 @default.
• W3118404775 cites W2078558642 @default.
• W3118404775 cites W2081716782 @default.
• W3118404775 cites W2098537659 @default.
• W3118404775 cites W2121153361 @default.
• W3118404775 cites W2121962845 @default.
• W3118404775 cites W2132588604 @default.
• W3118404775 cites W2142635246 @default.
• W3118404775 cites W2147455927 @default.
• W3118404775 cites W2155777530 @default.
• W3118404775 cites W2160367964 @default.
• W3118404775 cites W2164960433 @default.
• W3118404775 cites W2172181565 @default.
• W3118404775 cites W2332736166 @default.
• W3118404775 cites W2467060254 @default.
• W3118404775 cites W2485668101 @default.
• W3118404775 cites W2490019007 @default.
• W3118404775 cites W2552179547 @default.
• W3118404775 cites W2579916850 @default.
• W3118404775 cites W2746061356 @default.
• W3118404775 cites W2753432434 @default.
• W3118404775 cites W2777555897 @default.
• W3118404775 cites W2781337213 @default.
• W3118404775 cites W2891761236 @default.
• W3118404775 cites W2901191795 @default.
• W3118404775 cites W2902078827 @default.
• W3118404775 cites W2917722773 @default.
• W3118404775 cites W2943272229 @default.
• W3118404775 cites W2947601974 @default.
• W3118404775 cites W2966354200 @default.
• W3118404775 cites W2971507604 @default.
• W3118404775 cites W2972338824 @default.
• W3118404775 cites W2996270284 @default.
• W3118404775 cites W3042004622 @default.
• W3118404775 cites W4236098165 @default.
• W3118404775 cites W4252109704 @default.
• W3118404775 cites W4376595850 @default.
• W3118404775 doi "https://doi.org/10.1136/jitc-2020-001719" @default.
• W3118404775 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7805375" @default.
• W3118404775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33436486" @default.
• W3118404775 hasPublicationYear "2021" @default.
• W3118404775 type Work @default.
• W3118404775 sameAs 3118404775 @default.
• W3118404775 citedByCount "56" @default.
• W3118404775 countsByYear W31184047752021 @default.
• W3118404775 countsByYear W31184047752022 @default.
• W3118404775 countsByYear W31184047752023 @default.
• W3118404775 crossrefType "journal-article" @default.
• W3118404775 hasAuthorship W3118404775A5002744671 @default.
• W3118404775 hasAuthorship W3118404775A5017302019 @default.
• W3118404775 hasAuthorship W3118404775A5035031332 @default.
• W3118404775 hasAuthorship W3118404775A5039576853 @default.
• W3118404775 hasAuthorship W3118404775A5057402683 @default.
• W3118404775 hasAuthorship W3118404775A5064410348 @default.
• W3118404775 hasBestOaLocation W31184047751 @default.
• W3118404775 hasConcept C120665830 @default.
• W3118404775 hasConcept C121332964 @default.
• W3118404775 hasConcept C121608353 @default.
• W3118404775 hasConcept C126322002 @default.
• W3118404775 hasConcept C141071460 @default.
• W3118404775 hasConcept C207103383 @default.
• W3118404775 hasConcept C2776265017 @default.
• W3118404775 hasConcept C2777701055 @default.
• W3118404775 hasConcept C2778959117 @default.
• W3118404775 hasConcept C2780030458 @default.
• W3118404775 hasConcept C2780057760 @default.
• W3118404775 hasConcept C2780868729 @default.
• W3118404775 hasConcept C2781433595 @default.
• W3118404775 hasConcept C2908647359 @default.
• W3118404775 hasConcept C44249647 @default.
• W3118404775 hasConcept C61511704 @default.
• W3118404775 hasConcept C71924100 @default.
• W3118404775 hasConcept C72563966 @default.
• W3118404775 hasConcept C88879693 @default.

• next